Post-Approval watch: tracking a nerve tumor drug in real patients
NCT ID NCT06360406
Summary
This study is observing patients in Korea who are already taking Koselugo for neurofibromatosis type 1 (NF1) and its associated nerve tumors. Its main purpose is to monitor the drug's safety and see how well it works in everyday medical practice, outside of a controlled clinical trial. The study will follow 200 patients to collect real-world information on side effects and treatment outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBusan, South Korea
-
Research Site
RECRUITINGChungcheongbuk-do, South Korea
-
Research Site
RECRUITINGDaejeon, South Korea
-
Research Site
RECRUITINGGyeonggi-do, South Korea
-
Research Site
RECRUITINGIncheon, South Korea
-
Research Site
RECRUITINGJeonnam, South Korea
-
Research Site
SUSPENDEDSeoul, South Korea
-
Research Site
RECRUITINGSeoul, South Korea
-
Research Site
COMPLETEDSeoul, South Korea
-
Research Site
NOT_YET_RECRUITINGSeoul, South Korea
-
Research Site
RECRUITINGWŏnju, South Korea
-
Research Site
RECRUITINGYangsan, South Korea
Conditions
Explore the condition pages connected to this study.